Prevalence of visual field loss following exposure to vigabatrin therapy: A systematic review

Purpose:  Vigabatrin is an efficacious antiepileptic drug licensed as add‐on therapy in refractory epilepsy and used in infantile spasms. Eight years after licensing, there emerged a strong and possibly causative association with bilateral visual field loss. We report a systematic review ascertaining the magnitude of risk of vigabatrin associated visual field loss (VAVFL) and any clinical predictors of risk.

[1]  M. Baulac,et al.  Visual Field Loss in Patients with Refractory Partial Epilepsy Treated with Vigabatrin , 2009, CNS drugs.

[2]  E. Laska,et al.  Randomized, double-blind, placebo-controlled trial of vigabatrin for the treatment of cocaine dependence in Mexican parolees. , 2009, The American journal of psychiatry.

[3]  P. Smith,et al.  Nasal retinal nerve fiber layer attenuation: a biomarker for vigabatrin toxicity. , 2009, Ophthalmology.

[4]  E. Gaily,et al.  Visual fields at school‐age in children treated with vigabatrin in infancy , 2009, Epilepsia.

[5]  A. Hui,et al.  Vigabatrin-Induced Visual Dysfunction in Chinese Patients with Refractory Epilepsy , 2008, European journal of ophthalmology.

[6]  R. Hansen,et al.  Visual Fields in Children Treated With Vigabatrin , 2008 .

[7]  J. Tsai,et al.  Vigabatrin-attributable visual field defects in patients with intractable partial epilepsy. , 2006, Acta neurologica Taiwanica.

[8]  D. Goldstein,et al.  A pharmacogenetic exploration of vigabatrin-induced visual field constriction , 2006, Epilepsy Research.

[9]  T. Ko,et al.  Vigabatrin and Visual Field Defects in Pediatric Epilepsy Patients , 2006, Journal of Korean medical science.

[10]  R. Werth,et al.  Visual field loss in young children and mentally handicapped adolescents receiving vigabatrin. , 2006, Investigative ophthalmology & visual science.

[11]  P. Smith,et al.  Detecting vigabatrin toxicity by imaging of the retinal nerve fiber layer. , 2006, Investigative ophthalmology & visual science.

[12]  G. Cavalleri,et al.  Vigabatrin Retinopathy in an Irish Cohort: Lack of Correlation with Dose , 2006, Epilepsia.

[13]  S. Kochen,et al.  Visual Defects Associated with Vigabatrin: A Study of Epileptic Argentine Patients , 2005, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[14]  Anthony L. Johnson,et al.  The United Kingdom Infantile Spasms Study comparing vigabatrin with prednisolone or tetracosactide at 14 days: a multicentre, randomised controlled trial , 2004, The Lancet.

[15]  R. Schwartz,et al.  Superficial fungal infections , 2004, The Lancet.

[16]  G. Dutton,et al.  Peripheral retinal dysfunction in patients taking vigabatrin , 2003, Neurology.

[17]  F. Ascaso,et al.  Visual field defects in pediatric patients on vigabatrin monotherapy , 2003, Documenta Ophthalmologica.

[18]  H. Fledelius,et al.  [Vigabatrin and visual field defects. A Danish material with evaluation of different screening methods]. , 2003, Ugeskrift for laeger.

[19]  D. Chadwick,et al.  The legacy of vigabatrin in a regional epilepsy clinic , 2002, Journal of neurology, neurosurgery, and psychiatry.

[20]  W. Newman,et al.  Vigabatrin associated visual field loss: a clinical audit to study prevalence, drug history and effects of drug withdrawal , 2002, Eye.

[21]  S. Vanhatalo,et al.  Visual Field Constriction in 91 Finnish Children Treated with Vigabatrin , 2002, Epilepsia.

[22]  B. Schmitz,et al.  Visual field constriction in epilepsy patients treated with vigabatrin and other antiepileptic drugs: A prospective study , 2002, Journal of Neurology.

[23]  B. Polak,et al.  Visual field and electrophysiological abnormalities due to vigabatrin , 2002, Documenta Ophthalmologica.

[24]  P. Uldall,et al.  Vigabatrin and retinal changes , 2002, Documenta Ophthalmologica.

[25]  L. Laroche,et al.  Étude du champ visuel et traitement par vigabatrin chez l'enfant , 2001 .

[26]  R. Kälviäinen,et al.  No reversion in vigabatrin-associated visual field defects , 2001, Neurology.

[27]  H. Kıratlı,et al.  Rapid development of visual field defects associated with vigabatrin therapy , 2001, Eye.

[28]  H. Wieser,et al.  Concentric visual field restriction under vigabatrin therapy: extent depends on the duration of drug intake , 2001, Seizure.

[29]  E. Ben-Menachem,et al.  Vigabatrin Visual Toxicity: Evolution and Dose Dependence , 2001, Epilepsia.

[30]  G. Krauss,et al.  Visual Function is Stable in Patients Who Continue Long‐Term Vigabatrin Therapy: Implications for Clinical Decision Making , 2001, Epilepsia.

[31]  M. Engelsman,et al.  Visual Field Loss Associated with Vigabatrin: Quantification and Relation to Dosage , 2001 .

[32]  J. A. Mauri-Llerda,et al.  [Visual field changes secondary to vigabatrin treatment]. , 2000, Revista de neurologia.

[33]  G. Krauss,et al.  Visual function loss from vigabatrin. effect Of stopping the drug , 2000 .

[34]  U. Raucci,et al.  Visual Field Constriction in Children With Epilepsy on Vigabatrin Treatment , 2000, Pediatrics.

[35]  E. Brodtkorb,et al.  Visual field defects in patients taking vigabatrin. , 2000, Acta ophthalmologica Scandinavica.

[36]  E. Shahar,et al.  Visual impairment in children with epilepsy treated with vigabatrin , 2000, Annals of neurology.

[37]  A. Vignoli,et al.  Another case of reversibility of visual-field defect induced by vigabatrin monotherapy: is young age a favorable factor? , 2000, Neurological Sciences.

[38]  K. Krakow,et al.  Recovery of visual field constriction following discontinuation of vigabatrin1 1 Author to whom correspondence should be addressed; Dr. Karsten Krakow, MD, Neurologische Klinik, Klinikum der Goethe-Universitdt, Theodor-Stern-Kai 7, D-60590 Frankfurt, Germany. E-mail: k.krakow@em.uni-frankfurt.de , 2000, Seizure.

[39]  T. Berendschot,et al.  Concentric Contraction of the Visual Field in Patients with Temporal Lobe Epilepsy and Its Association with the Use of Vigabatrin Medication , 2000, Epilepsia.

[40]  S. Nightingale,et al.  A controlled study of vigabatrin and visual abnormalities , 2000, The British journal of ophthalmology.

[41]  D. Mackey,et al.  Vigabatrin-associated visual field defects in children , 2000, Eye.

[42]  P. Derambure,et al.  The relationship of MS to physical trauma and psychological stress: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. , 2000, Neurology.

[43]  G. Harding,et al.  Visual field defects associated with vigabatrin therapy , 1999, Journal of neurology, neurosurgery, and psychiatry.

[44]  G. Harding,et al.  Characteristics of a Unique Visual Field Defect Attributed to Vigabatrin , 1999, Epilepsia.

[45]  R. Mann,et al.  Visual field defect associated with vigabatrin: observational cohort study , 1999, BMJ.

[46]  J. Partanen,et al.  Vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field defects , 1999, Neurology.

[47]  P. Kertes,et al.  Symptomatic and asymptomatic visual loss in patients taking vigabatrin. , 1999, Ophthalmology.

[48]  E. Boltshauser,et al.  Visual field constriction is not limited to children treated with vigabatrin. , 1999, Neuropediatrics.

[49]  S. Lhatoo,et al.  Infantile spasms and vigabatrin. Visual field defects may be permanent. , 1999, BMJ.

[50]  M. Brigell.  Vigabatrin-associated retinal cone system dysfunction , 1998, Neurology.

[51]  Katsumi Nakamura,et al.  Changes in N‐Acetylaspartate Levels in the Basal Ganglia of Patients with a Schizophrenia‐Like Epileptic Psychosis , 1998 .

[52]  G. Smith,et al.  Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.

[53]  T Eke,et al.  Retrospective study of concussive convulsions in elite Australian rules and rugby league footballers: phenomenology, aetiology, and outcome , 1997, BMJ.

[54]  A. Marson,et al.  New antiepileptic drugs: a systematic review of their efficacy and tolerability , 1996, BMJ.

[55]  P. Schechter,et al.  Clinical pharmacology of vigabatrin. , 1989, British journal of clinical pharmacology.

[56]  R. Heel,et al.  Vigabatrin , 2012, Drugs.

[57]  E. Marszał,et al.  [The function of eye and vision system in children and youth treated with vigabatrin--our own experiences]. , 2005, Klinika oczna.

[58]  N. Miladi,et al.  Treatment of infantile spasms. , 1991, Pediatric neurology.